A Study to Test if TEV-48574 is Effective in Relieving Asthma

  • End date
    Aug 17, 2022
  • participants needed
  • sponsor
    Teva Branded Pharmaceutical Products R&D, Inc.
Updated on 10 January 2022


The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).

The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.

The duration of patient participation in the study is planned to be up to approximately 30 weeks.

Condition Asthma
Treatment Placebo, TEV-48574
Clinical Study IdentifierNCT04545385
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
Last Modified on10 January 2022


Yes No Not Sure

Inclusion Criteria

The participant has a diagnosis of asthma for at least 12 months prior to the initial screening visit
The participant is able to perform technically acceptable and repeatable spirometry, including with a hand-held spirometer, after training
The participant has had at least one documented clinical asthma exacerbation in the 18 months prior to (but not within 30 days of) the initial screening visit
The participant is a non-smoker for ≥6 months with lifetime history ≤10 pack-years, with no current ecigarette or marijuana use
NOTE- Additional criteria apply, please contact the investigator for more

Exclusion Criteria

The participant has any concomitant conditions or treatments that could interfere with study conduct
The participant is currently pregnant or lactating or is planning to become pregnant during the study
The participant has received any live or attenuated vaccine within 15 days of the initial screening visit
NOTE- Additional criteria apply, please contact the investigator for more
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note